Analyst Reco. Vertex Pharmaceuticals Incorporated

Equities

VRTX

US92532F1003

Market Closed - Nasdaq Other stock markets 04:00:00 2024-06-06 pm EDT			5-day change	1st Jan Change
485.5 ^USD	+0.52%		+10.07%	+19.33%

Jun. 05	Vertex Pharmaceuticals Insider Sold Shares Worth $1,495,000, According to a Recent SEC Filing	MT
Jun. 05	Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vertex Pharmaceuticals Insider Sold Shares Worth $1,000,500, According to a Recent SEC Filing	Jun. 05	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $2,033,159, According to a Recent SEC Filing	Jun. 03	MT
BMO Capital Adjusts Price Target on Vertex Pharmaceuticals to $500 From $480	May. 31	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $1,478,068, According to a Recent SEC Filing	May. 31	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $715,205, According to a Recent SEC Filing	May. 29	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $3,168,704, According to a Recent SEC Filing	May. 24	MT
Vertex Pharmaceuticals Insider Sold Shares Worth $6,795,294, According to a Recent SEC Filing	May. 22	MT
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $520 From $497	May. 14	MT
ANALYST RECOMMENDATIONS : Nvidia, The Home Depot, Lowe's, Rollins...	May. 07
Leerink Partners Adjusts Vertex Pharmaceuticals' Price Target to $529 From $511	May. 07	MT
Stifel Adjusts Vertex Pharmaceuticals' Price Target to $420 From $430	May. 07	MT
Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $456 From $450, Keeps Overweight Rating	May. 07	MT
Morgan Stanley Adjusts Price Target on Vertex Pharmaceuticals to $402 From $413, Keeps Equalweight Rating	May. 07	MT
RBC Adjusts Price Target on Vertex Pharmaceuticals to $424 From $417, Keeps Sector Perform Rating	May. 07	MT
Goldman Sachs Adjusts Price Target on Vertex Pharmaceuticals to $577 From $574, Keeps Buy Rating	May. 07	MT
Bernstein Adjusts Price Target on Vertex Pharmaceuticals to $458 From $450, Keeps Market Perform Rating	May. 07	MT
Wolfe Research Adjusts Price Target on Vertex Pharmaceuticals to $497 From $515	Apr. 25	MT
UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating	Apr. 17	MT
Guggenheim Adjusts Vertex Pharmaceuticals' Price Target to $450 From $445	Apr. 17	MT
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	Apr. 11	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

Vertex Pharmaceuticals Incorporated : Vertex and Crispr to market $2.2 million treatment for sickle cell disease

December 11, 2023 at 05:47 am EST